Evaluation of the effectiveness of chemical inactivation and immunogenicity of the Omicron variant of the SARS-CoV-2 virus
Problems of Virology · 2024
DOI: 10.36233/0507-4088-253 ↗Kurz gefasst
Fachartikel in der Zeitschrift Problems of Virology, 2024. Verfasst von G A Zhapparova und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Biological Safety Problems. Hauptthemen laut MEDLINE: SARS-CoV-2, Virus Inactivation, Propiolactone, Formaldehyde. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The rapid spread of coronavirus infection COVID-19 among the population of many countries around the world has contributed to the emergence of many genetic variants of SARS-CoV-2. Compared to previous coronavirus variants, the new Omicron variants have shown a noticeable degree of mutation. Virus inactivation is one of the most important steps in the development of inactivated vaccines. The chemical inactivation agents currently used are β-propiolactone and formaldehyde, but there is no uniform standard for designing and specifying the inactivation process.
Objective
Evaluation and comparison of the effectiveness of chemical inactivation of two agents, formaldehyde and β-propiolactone against immunogenicity of the Omicron variant of the SARS-CoV-2 virus. Materials and methods. Nasopharyngeal swabs were used to obtain the SARS-CoV-2 Omicron variant virus. Vero cell culture was used to isolate, reproduce, titrate the virus, and perform a neutralization reaction. The kinetics of studying the inactivation of the virus by chemical agents such as formaldehyde and β-propiolactone was carried out.
Results
Studies have been conducted to comparatively evaluate the effectiveness of chemical agents used to inactivate the SARS-CoV-2 virus of the Omicron variant, planned for use in the production of an inactivated whole-virion vaccine. Formaldehyde and β-propiolactone were used as inactivation agents in concentrations of 0.05, 0.1, 0.5% of the total volume of the virus suspension. It has been established that complete inactivation of the virus by formaldehyde in the concentrations used at a temperature of 37 °C occurs within up to 2 hours, and when using beta-propiolactone, within up to 12 hours.
Conclusion
Inactivated virus samples have different antigenic activity depending on the concentration of the inactivation agents used. The most pronounced antigenic activity is manifested in samples of the pathogen that were treated with an inactivation agent at a mild concentration of 0.05%. Increasing the concentration of inactivation agent by 5 or more times leads to a significant decrease in the antigenicity of the SARS-CoV-2 virus. With the inactivation modes used, the loss of biological activity of the virus occurs faster and antigenicity is retained largely when treated with formaldehyde.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Institute for Biological Safety Problems.
ORCID-Profile: G A Zhapparova, B S Myrzakhmetova, T M Tlenchiyeva, A A Tussipova, K B Bissenbayeva, A S Toytanova, L B Kutumbetov
Zitieren
APA
Zhapparova, G. A., Myrzakhmetova, B. S., Tlenchiyeva, T. M., Tussipova, A. A., Bissenbayeva, K. B., Toytanova, A. S., & Kutumbetov, L. B. (2024). Evaluation of the effectiveness of chemical inactivation and immunogenicity of the Omicron variant of the SARS-CoV-2 virus. Problems of Virology. https://doi.org/10.36233/0507-4088-253
Vancouver
Zhapparova GA, Myrzakhmetova BS, Tlenchiyeva TM, Tussipova AA, Bissenbayeva KB, Toytanova AS, et al. Evaluation of the effectiveness of chemical inactivation and immunogenicity of the Omicron variant of the SARS-CoV-2 virus. Problems of Virology. 2024. doi:10.36233/0507-4088-253
BibTeX
@article{Zhapparova2024,
author = {Zhapparova, G A and Myrzakhmetova, B S and Tlenchiyeva, T M and Tussipova, A A and Bissenbayeva, K B and Toytanova, A S and Kutumbetov, L B},
title = {Evaluation of the effectiveness of chemical inactivation and immunogenicity of the Omicron variant of the SARS-CoV-2 virus},
journal = {Problems of Virology},
year = {2024},
doi = {10.36233/0507-4088-253}
}
EUVIMED